Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Calidi BiotherapeuticsCLDI -4.96%11 Price-to-Tangible-Book is 0.83 as of Sep. 11, 2026. GuruFocus rates CLDI with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Calidi Biotherapeutics ranks better than 90.06% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Calidi Biotherapeutics Price-to-Tangible-Book Related Terms
Calidi Biotherapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Calidi Biotherapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLDI vs ARTL, CRIS, SXTP: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Calidi Biotherapeutics (CLDI) has a Price-to-Tangible-Book of 0.83 as of Sep. 11, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #112 out of 1127 companies in the Biotechnology industry, placing it in the top 9.9%.
Is Calidi Biotherapeutics' Price-to-Tangible-Book too high?
Calidi Biotherapeutics' current Price-to-Tangible-Book is 0.83. The Biotechnology industry median Price-to-Tangible-Book is 3.27. Calidi Biotherapeutics' value of 0.83 is 74.6% below this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #112 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Price-to-Tangible-Book compare to ARTL and CRIS?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #112 out of 1127 companies for Price-to-Tangible-Book. This places Calidi Biotherapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.27. Calidi Biotherapeutics' value of 0.83 is 74.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.27, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current Price-to-Tangible-Book of 0.83 is 74.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current Price-to-Tangible-Book is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Price-to-Tangible-Book of 0.83. The current Price-to-Tangible-Book is 0.83 and 74.6% below the Biotechnology industry median of 3.27. Calidi Biotherapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Price-to-Tangible-Book is 0.83 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
11GF Score
Get the complete analysis for CLDI
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
